Veeva Systems Inc. (VEEV) Stock Valuation — DCF Analysis
Medical - Healthcare Information Services · NYSE
Current Price
$159.54
Intrinsic Value
$237.89
+32.9% margin of safety
COMPETITIVE MOAT
↑Deep Pharma Cloud Integration
Veeva's comprehensive cloud suite is deeply embedded in biopharmaceutical workflows, creating significant switching costs for customers. This integration is further strengthened by new AI capabilities.
↑AI-Powered Workflow Automation
The introduction of Falcon AI agents and their integration into existing platforms like CRM enhances efficiency. This advanced automation makes Veeva's solutions indispensable for drug development and commercialization.
↑Strong Customer Relationships & Data
Long-standing relationships and the vast amount of proprietary data within Veeva's ecosystem create a network effect. This data advantage fuels AI development and customer stickiness.
INVESTMENT RISKS
↓Intensifying AI Competition
While Veeva is pushing AI, the broader tech sector's rotation away from tech stocks suggests increased competition and potential commoditization of AI features. Competitors may offer similar AI solutions.
↓Execution of AI Strategy
The success of Veeva's AI push, particularly with Falcon agents, hinges on seamless integration and demonstrable value. Any missteps in execution could impact customer adoption and future growth.
↓Regulatory Landscape Shifts
The biopharmaceutical industry is heavily regulated. Changes in regulatory requirements could necessitate significant platform updates, potentially impacting Veeva's development roadmap and costs.
Base case
VEEV base case valuation
A base case discounted cash flow model for VEEV estimates an intrinsic value of about $237.89 per share, against a current price of $159.54. The model assumes 12.8% annual free cash flow growth, a 10.0% discount rate, and a 16x exit multiple.
Intrinsic Value
$237.89
Margin of safety
+32.9%
Expected annual return
+8.3%
Base case assumptions: 12.8% annual growth, 10.0% discount rate, 16x exit multiple, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the VEEV valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Veeva Systems Inc. respond.
Open DCF Calculator for VEEVCompany Overview
Veeva Systems Inc. is a leading provider of cloud-based software solutions, exclusively dedicated to the global life sciences industry. Its extensive operational presence spans across North America, Europe, the Asia Pacific region, the Middle East, Africa, and Latin America. The company's product portfolio is primarily structured around two major offerings. First, the Veeva Commercial Cloud delivers an integrated suite of software, data, and analytics tools designed to optimize commercial operations. This includes vital applications such as Veeva Customer Relationship Management (CRM) and its specialized Medical CRM, Veeva Closed Loop Marketing (CLM), sophisticated analytics via Veeva CRM MyInsights, approved email communication with Veeva CRM Approved Email, digital engagement tools like Veeva CRM Engage, commercial alignment through Veeva Align, event management capabilities with Veeva CRM Events Management, data warehousing solutions (Veeva Nitro), data services (Veeva OpenData, Veeva Link), master data management (Veeva Network), advanced analytical insights (Veeva Crossix, Veeva Data Cloud), and patient engagement platforms (MyVeeva for Patients). Secondly, Veeva Vault provides a robust collection of cloud-native enterprise content and data management applications. These applications are engineered to support both critical commercial functions—encompassing sales, marketing, and medical content and communications—and comprehensive research and development processes, including clinical trials, regulatory compliance, quality management, and patient safety. Beyond its software, Veeva offers a wide array of professional and support services. These range from strategic implementation and deployment planning, project management, and detailed requirements analysis to solution design and configuration. They also include system environment management and deployment, expert consulting for business process transformation related to Veeva solutions, technical guidance on data migration and systems integrations, comprehensive training programs, and ongoing managed services such as outsourced systems administration. Tracing its origins, the company was incorporated in 2007 as Verticals onDemand, Inc., and subsequently rebranded to Veeva Systems Inc. in April 2009. Its corporate headquarters are situated in Pleasanton, California.
Financial Metrics — VEEV Stock Valuation Data
Revenue/Share (TTM)
$20.32
FCF/Share (TTM)
$10.06
ROIC (TTM)
9.7%
ROE (TTM)
13.4%
P/FCF
15.8x
EV/EBITDA
18.7x
FCF Yield
6.34%
Debt/Equity
0.01x
Based on trailing twelve-month data, VEEV shows a free cash flow per share of $10.06 and a ROIC of 9.7%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 15.8x and FCF yield of 6.34% are important context metrics when evaluating VEEV's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of VEEV?
Veeva Systems Inc. currently generates $10.06 in free cash flow per share. At the current price of $159.54, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is VEEV undervalued?
VEEV trades at a P/FCF ratio of 15.8x with a free cash flow yield of 6.34%. This P/FCF is in a moderate range. However, whether VEEV is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value VEEV stock using DCF?
To perform a DCF valuation on Veeva Systems Inc.: (1) Start with the trailing free cash flow per share ($10.06) as the base, (2) project future FCF growth over 5-10 years based on Medical - Healthcare Information Services industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting VEEV's risk profile — with a debt-to-equity of 0.01x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to VEEV?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Veeva Systems Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Healthcare Information Services trends, then discounting those amounts to today's dollars. VEEV's ROIC of 9.7% shows moderate capital returns.
How does WACC affect VEEV stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For VEEV, with a debt-to-equity ratio of 0.01x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 18.7x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See VEEV PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value VEEV with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.